Lactic Acidosis with an Isolated Cytochrome c Oxidase Defect
A 19-year-old woman is referred for a decade of exercise intolerance, recurrent vomiting with febrile illness, and mild proximal weakness. Resting venous lactate is 6.8 mmol/L (reference <2.2) and pyruvate 0.09 mmol/L (reference 0.03–0.10); the lactate-to-pyruvate ratio is 76 (reference <20). Blood alanine is elevated. Muscle biopsy shows subsarcolemmal accumulations that stain with Gomori trichrome (ragged red fibers). Respiratory-chain enzymology on a fresh muscle homogenate, expressed as a percentage of the mean of age-matched controls and normalized to citrate synthase, gives: complex I 92%, complex II 105%, complex III 88%, complex IV 31%; citrate synthase activity is 140% of control. Cultured skin fibroblasts grow normally in glucose-containing medium but fail to grow when galactose replaces glucose. The family asks whether the problem is in pyruvate metabolism or in the respiratory chain, and whether a 'mitochondrial vitamin cocktail' is worth trying.
1. Using the lactate-to-pyruvate ratio and the fibroblast growth result, argue whether the primary defect is pyruvate dehydrogenase or the respiratory chain. What does the galactose result add?
Read the worked answer
The lactate-to-pyruvate ratio is the key discriminator. In pyruvate dehydrogenase (PDH) deficiency, pyruvate accumulates and is partly converted to lactate, so both rise together and the ratio stays normal or low; alanine is also high. Here lactate is 6.8 mmol/L with pyruvate only 0.09 mmol/L, giving a ratio of about 76, far above the reference of <20. That pattern means pyruvate is being delivered to the mitochondrion but NADH is not being reoxidized efficiently, so the equilibrium of lactate dehydrogenase is pushed toward lactate. The galactose growth test adds functional evidence: in galactose medium, cells cannot generate enough ATP from glycolysis and must rely on oxidative phosphorylation; normal growth in glucose but failure in galactose is a classic screen for an oxidative phosphorylation defect. Together, the data point to the respiratory chain, not PDH. A PDH defect would not explain the isolated complex IV deficiency or the galactose failure. The ratio is not perfectly specific because severe hypoperfusion or other mitochondrial defects can raise it, so it must be interpreted with the enzyme and functional data.
2. The enzyme data show complex II activity is normal while complex IV is low, and citrate synthase is high. Explain both findings and what they imply about whether the defect is encoded by mitochondrial DNA or nuclear DNA. State the limits of this inference.
Read the worked answer
Complex II is unusual because all four of its subunits are encoded by nuclear DNA; it contains no mitochondrial-DNA-encoded subunit. A global mitochondrial translation defect, such as a tRNA mutation or a large mtDNA deletion, therefore typically leaves complex II activity intact while lowering complexes I, III, and IV. Here complex II is 105% of control, but the deficiency is isolated to complex IV (31%), not a combined I/III/IV pattern. That favors a defect in a complex IV assembly factor or subunit rather than a global mtDNA translation defect. Many COX assembly factors (for example SURF1, SCO2, COX10, COX15) are nuclear-encoded, and isolated COX deficiency in a young patient is often nuclear. However, mtDNA-encoded COX subunits (COX I–III) and mtDNA tRNA mutations can also cause isolated COX deficiency, sometimes with mosaic COX-negative fibers. The high citrate synthase (140%) is a compensatory increase in mitochondrial mass, not the primary lesion. Enzyme data alone cannot prove nuclear versus mtDNA origin; sequencing of nuclear COX genes and mtDNA is required, and the pattern of affected relatives would help.
3. The parents ask about a supplement containing riboflavin, coenzyme Q10, and L-carnitine. Based on the data, evaluate each component's rationale. What monitoring would you require before calling any trial a success?
Read the worked answer
Riboflavin is the precursor of FMN and FAD, cofactors for complexes I and II, not for complex IV; there is no biochemical rationale for correcting an isolated COX defect, and high doses mainly cause harmless yellow urine. Coenzyme Q10 carries electrons from complexes I and II to complex III; if the block is at complex IV, CoQ10 is downstream of the electron entry points and is unlikely to bypass the lesion, although secondary CoQ10 deficiency has been reported in some mitochondrial disorders. L-carnitine can help only if there is secondary carnitine deficiency or a fatty-acid oxidation defect; it is not a treatment for COX deficiency, and unnecessary supplementation has costs and can alter metabolite profiles. A fair trial would first define objective endpoints (growth, 6-minute walk distance, lactate during standardized exercise, muscle MRI spectroscopy), use a placebo or run-in design where feasible, set a pre-specified duration, and monitor for adverse effects and drug interactions. A subjective 'feels better' report should not be called success, and the cocktail should not delay genetic diagnosis or genetic counseling.